prempro- conjugated estrogens and medroxyprogesterone acetate tablet, sugar coated
avera mckennan hospital - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - estrogens, conjugated 0.625 mg - prempro or premphase therapy should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or a history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to prempro/premphase - known liver dysfunction or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy prempro and premphase should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. prempro and premphase should not be used during lactation. estrogen administration to nursing women has been shown t
duavee- conjugated estrogens/bazedoxifene tablet, film coated
u.s. pharmaceuticals - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), bazedoxifene acetate (unii: j70472ud3d) (bazedoxifene - unii:q16tt9c5bk) - estrogens, conjugated 0.45 mg - duavee is indicated in women with a uterus for: - use duavee for the shortest duration consistent with treatment goals and risks for the individual woman. postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary. - when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered. duavee is contraindicated in women with any of the following conditions: - undiagnosed abnormal uterine bleeding - known, suspected, or past history of breast cancer - known or suspected estrogen-dependent neoplasia - active deep venous thrombosis, pulmonary embolism, or history of these conditions - active arterial thromboembolic disease (for example, stroke, myocardial infarction) or history of these conditions - hypersensitivity (for example, anaphylaxis, angioedema) to estrogens, bazedoxifene, or any ingredients -
premarin 0.625mg/g vaginal cream
pfizer ltd - conjugated oestrogens - vaginal cream - 625microgram/1gram
premarin 2.5mg tablets
wyeth pharmaceuticals - conjugated oestrogens - oral tablet - 2.5mg
premarin 25mg powder and solvent for solution for injection vials
imported (switzerland) - conjugated oestrogens - powder and solvent for solution for injection - 25mg
premarin 25mg powder for solution for injection vials
imported (canada) - conjugated oestrogens - powder for solution for injection - 25mg
esocon 0.625 tablet
incepta pharmaceuticals ltd. - conjugated oestrogens - tablet - 625 mcg
esocon tablet
incepta pharmaceuticals ltd. (dhamrai unit) - conjugated oestrogens - tablet - 625 mcg
estracon tablet
renata limited - conjugated oestrogens - tablet - 625 mcg
premicon tablet
techno drugs ltd. - conjugated oestrogens - tablet - 625 mcg